Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01783288 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2025 to Dec 2026v21
  2. Primary and study completion dates: Jan 2025 to Dec 2025v20
  3. Primary and study completion dates: Sep 2024 to Jan 2025v19
  4. Primary and study completion dates: Jun 2024 to Sep 2024v18
  5. Primary and study completion dates: Mar 2024 to Jun 2024v17
Show 15 earlier versionsHide 15 earlier versions
  1. Primary and study completion dates: Dec 2023 to Mar 2024v16
  2. 2 versions Re-verified since Nov 22, 2022, no change to tracked fieldsv14-v15
  3. Primary and study completion dates: Dec 2021 to Dec 2023v13
  4. Re-verified, no change to tracked fieldsv12
  5. Primary and study completion dates: Dec 2020 to Dec 2021v11
  6. Primary and study completion dates: Dec 2019 to Dec 2020v10
  7. Primary and study completion dates: Dec 2018 to Dec 2019v9
  8. Primary and study completion dates: Feb 2018 to Dec 2018v8
  9. Study site revisedv7
  10. Primary and study completion dates: Feb 2017 to Feb 2018v6
  11. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  12. Collaborators expanded, about 12 wordsv4
  13. 2 versions Re-verified since Dec 18, 2014, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to determine whether patients meet criteria for Postural Tachycardia Syndrome (or not) and have reduced blood volume (or not). Both of these are important screening elements to Aim 3 of a National Institutes of Health Grant. The purposes of Aim 3 are to determine 1. whether a high dietary sodium level appropriately expands plasma volume in Postural Orthostatic Tachycardia, 2. whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in Postural Tachycardia Syndrome and 3. whether patients with Postural Tachycardia Syndrome have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.
Trial Details
NCT Number NCT01783288
Lead Sponsor Vanderbilt University
Collaborators: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Postural Tachycardia Syndrome
Related terms Orthostatic Intolerance, Postural Orthostatic Tachycardia Syndrome
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov